178 related articles for article (PubMed ID: 15634486)
21. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina.
Masuzawa K; Jesmin S; Maeda S; Zaedi S; Shimojo N; Miyauchi T; Goto K
Exp Biol Med (Maywood); 2006 Jun; 231(6):1090-4. PubMed ID: 16741055
[TBL] [Abstract][Full Text] [Related]
22. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
Phipps JA; Wilkinson-Berka JL; Fletcher EL
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):927-34. PubMed ID: 17251496
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet.
Weisinger RS; Stanley TK; Begg DP; Weisinger HS; Spark KJ; Jois M
Physiol Behav; 2009 Aug; 98(1-2):192-7. PubMed ID: 19465040
[TBL] [Abstract][Full Text] [Related]
24. [Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on angiogenesis of gastric cancer in a nude mouse model].
Wang L; Cai SR; Zhang CH; He YL; Zhan WH; Wu H; Peng JJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Nov; 11(6):565-8. PubMed ID: 19031137
[TBL] [Abstract][Full Text] [Related]
25. Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade.
Feng TC; Ying WY; Hua RJ; Ji YY; de Gasparo M
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):19-24. PubMed ID: 11881060
[TBL] [Abstract][Full Text] [Related]
26. Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats.
Awad AS; Webb RL; Carey RM; Siragy HM
Am J Hypertens; 2005 Apr; 18(4 Pt 1):544-8. PubMed ID: 15831366
[TBL] [Abstract][Full Text] [Related]
27. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
28. Valsartan, captopril, or both in myocardial infarction.
McAnulty JH
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14985495
[No Abstract] [Full Text] [Related]
29. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats.
Kusari J; Zhou S; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5152-9. PubMed ID: 17962468
[TBL] [Abstract][Full Text] [Related]
30. [Effects of cilazapril on the expression of vascular endothelial growth factor and intercellular adhesion molecule-1 in diabetic rat glomeruli].
Lin H; Huang S; Mi X; Sha Z
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):694-7. PubMed ID: 14619584
[TBL] [Abstract][Full Text] [Related]
31. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice.
Ebrahimian TG; Tamarat R; Clergue M; Duriez M; Levy BI; Silvestre JS
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):65-70. PubMed ID: 15528473
[TBL] [Abstract][Full Text] [Related]
32. Valsartan, captopril, or both in myocardial infarction.
Jorde UP
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
[No Abstract] [Full Text] [Related]
33. Valsartan, captopril, or both in myocardial infarction.
Moshenyat R; Kupfer Y; Tessler S
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
[No Abstract] [Full Text] [Related]
34. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats.
Rota R; Chiavaroli C; Garay RP; Hannaert P
Eur J Pharmacol; 2004 Jul; 495(2-3):217-24. PubMed ID: 15249173
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanism of limbs' postischemic revascularization improved by perindopril in diabetic rats.
Gao L; Yu DM
Chin Med J (Engl); 2008 Nov; 121(21):2129-33. PubMed ID: 19080171
[TBL] [Abstract][Full Text] [Related]
36. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy.
Cheung R; Lewanczuk RZ; Rodger NW; Huff MW; Oddou-Stock P; Botteri F; Pecher E; Muirhead N
Int J Clin Pract; 1999 Dec; 53(8):584-92. PubMed ID: 10692751
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
38. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
Estacio RO; Coll JR; Tran ZV; Schrier RW
Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
[TBL] [Abstract][Full Text] [Related]
39. [The preliminary studies on the cross action between endothelin-1 and angiotensin II in kidney tissue of rats with diabetic nephropathy].
Cheng H; Tian XF; Dong HR; Ding SS; Qiu CB; Chen YP
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(3):248-52. PubMed ID: 15059549
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
